

Surrey & North West Sussex Area Prescribing Committee

Policy Statement	Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (NICE TA590)
Policy No:	APC 460-2019
Date of Issue	November 2019
Review Date:	<p><i>No review date will be assigned to any drugs or devices that are subject to a NICE Technology appraisal.</i></p> <p><i>The recommendation made by the APC (formerly PCN) will be reviewed when new published evidence becomes available OR there is new published national guidance e.g. NICE)</i></p>
<p>Recommendations:</p> <p>The Area Prescribing Committee recommends fluocinolone acetonide as a treatment option in recurrent non-infectious uveitis in line with NICE TA590 Fluocinolone acetonide intravitreal implant will be considered RED on the traffic light system</p> <p>Prescribing would be by hospital specialists only, in line with NICE TA596 using the Blueteq initiation and continuation forms.</p> <p>Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.</p>	
<p>Key Considerations:</p> <ul style="list-style-type: none"> NICE TA590 - Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (July 2019) https://www.nice.org.uk/guidance/ta590/resources/fluocinolone-acetonideintravitreal-implant-for-treating-recurrent-noninfectious-uveitis-pdf82607257019077 	
Date taken to Area Prescribing Committee	6 th November 2019
Agreed by APC members	19 th November 2019